Table 3.
Characteristics of studies re-analyzed in this review.
| Study | Year | Population | nGV | nMI | nMII | Ovarian Stimulation | Oocytes/Follicles Collection and Processing | RNA-Seq |
|---|---|---|---|---|---|---|---|---|
| Reyes et al. [29]. | 2017 |
n = 5 (1 GV and 1 IVM-MII for each patient) Age: n = 5 < 30 yo (26.8, 20–29/n = 5 >= 40 yo (41.6, 40–43) Varying causes of infertility |
10 | 10 | FSH + hCG for final follicular maturation | GV processed immediately MII obtained after 24 h IVM |
Isolation: PicoPure RNA Isolation kitRT: anchored oligo(dT) Library: Thruplex DNA-seq kit Sequencing: Illumina paired-end 100 bp (HiSeq2500) |
|
| Yu et al. [26] | 2020 |
n = 17 Age: GV 35.3 yo (28–41), MI 36.1 yo (32–41), MII 32.6 yo (27–39) |
7 | 7 | 7 | Unknown | MII from oocyte donors who had excess oocytes that removed them from donor list | RT: SMART-Seq v4 ultra low input RNA kit Library: Illumina TruSeq |
| Ntostis et al. [28] | 2021 |
n = 12 Age: n = 6 21.6 yo (21–26 yo)/n = 6 42.0 yo (41–44 yo) Young maternal age group = oocyte donor Advanced maternal age = unexplained infertility, male infertility or age |
10 | 11 | Short GnRH agonist protocol + rFSH + hCG trigger | In vivo matured | RT: SMART-Seq v4 ultra low input RNA kit Library: Illumina’s Nextera XT Sequencing: Illumina sequencing 150 bp (HiSeq3000) |
|
| Llonch et al. [27] | 2021 |
n = 37 (25 donors, 12 patients) Age: 28.8 yo (18–43) AFC: 22.1 (4–46) Patient: advanced maternal age or male factor infertility |
44 | 31 | GnRH antagonist + FSH or HP-hMG + hCG or triptorelin | GV processed immediately MII obtained after 30 h IVM |
Smart-seq2 protocol RT: SuperScript II with oligo-dT Library: Illumina’s Nextera XT Sequencing: Illumina paired-end 75 bp (HiSeq4000) |
|
| Hu et al. [25] | 2022 | Age: <35 yo | 9 | 5 | GnRH antagonist or long agonist protocol, hCG trigger | 2 replicates of 10 pooled oocytes from different donors (for GV and MII) or single oocytes Oocytes were vitrified/thawed |
T&T-seq Isolation: TRIzol + isopropanol RT: Single Cell Full-Length mRNA-Amplification Kit Library: TruePrep® DNA Library Prep Kit V2 Sequencing: (Novaseq 6000) |
|
| Takeuchi et al. [24] | 2022 |
n = 11 Age: 30–39 yo |
7 | 6 | 6 | Surplus oocytes other than the MII stage were subjected to IVM: GV, MI, and MII collected after IVM Oocytes that remained immature at the time sampling were left in the maturation medium overnight and examined on the next day of the oocyte retrieval 4 GV, 3 MI, 3 MII after 7.5–9 h IVM 3 GV, 3 MI, 3 MII after 15–16.5 h IVM |
RT: SMART- seq v4 Ultra Low Input RNA Kit Library: Nextera XT DNA Library Preparation Kit Sequencing: paired-end 50 bp + 25 bp (NextSeq) |
|
| 87 | 13 | 70 | ||||||
| Zhang et al. [23] | 2018 |
n = 8 Age: 27.7 yo (24–32) Sex reassignment surgery, cervical cancer, endometrial cancer, benign ovarian mass, or lymphoma but without histopathological abnormality |
n = 17 primordial follicles n = 25 primary follicles n = 12 secondary follicles n = 23 antral follicles |
NA | Library: Kappa Hyper Prep Kit | |||
AFC: antral follicle count; FSH: follicle-stimulating hormone; GnRH-a: gonadotrophin-releasing hormone; GV: germinal vesicle; hCG: human chorionic gonadotrophin; HP-hMG: highly purified human menopausal gonadotrophin; IVM: in vitro maturation; MI: metaphase I; MII: metaphase II; RT: retrotranscription.